Codexis to sell Pompe, Fabry assets to Crosswalk Therapeutics (NASDAQ:CDXS)
2024-07-01
Dzmitry Skazau/iStock via Getty Images Codexis (NASDAQ:CDXS) said it has finalized a sales agreement with Crosswalk Therapeutics for its gene therapy programs for Fabry and Pompe disease that were discontinued by partner Takeda (TAK) in April 2023. Under the agreement, Codexis will be eligible to receive development and commercial milestoneContinue Reading